Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews · Heart

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 75%Low 1 · 25%Moderate 0 · 0%High 0 · 0%

Levosimendan vs dobutamine

All‐cause short‐term mortality: range 15 to 31 days · people with cardiogenic shock or low cardiac output syndrome

Levosimendan showed no clear difference in all‐cause short‐term mortality: range 15 to 31 days compared with dobutamine (low certainty).

1 finding from 1 review

Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes only
RR 0.6 [0.36, 1.03]
4 studies · 1701 participants
Low

Epinephrine vs norepinephrine

All‐cause short‐term mortality: 28 daysÂ · adults with cardiogenic shock

It is very uncertain whether epinephrine changes all‐cause short‐term mortality: 28 daysÂ compared with norepinephrine (very low certainty).

1 finding from 1 review

Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes only
RR 1.81 [0.89, 3.68]
1 study · 57 participants
Very low

Levosimendan vs enoximone

All‐cause short‐term mortality: 30 days · adults with cardiogenic shock

It is very uncertain whether levosimendan changes all‐cause short‐term mortality: 30 days compared with enoximone (very low certainty).

1 finding from 1 review

Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes only
RR 0.5 [0.22, 1.14]
1 study · 32 participants
Very low

Epinephrine vs norepinephrine‐dobutamine

All‐cause short‐term mortality: 28 days · adults with cardiogenic shock

It is very uncertain whether epinephrine changes all‐cause short‐term mortality: 28 days compared with norepinephrine‐dobutamine (very low certainty).

1 finding from 1 review

Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes only
RR 1.25 [0.41, 3.77]
1 study · 30 participants
Very low